Replies to post #195975 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Pain Suppression, Of Every Kind

Ok, AV1066, Anavex’s new analgesic works against all of the pains listed here (from the patent document):

Hyperalgesia is an increased sensitivity to pain, which in one form is caused by damage to nociceptors in the body's soft tissues. Anti-hyperalgesic is a property to reduce such pain sensitivity (i.e., a positive effect).
Visceral pain or nociceptive is pain that results from the activation of nociceptors of the thoracic, pelvic, or abdominal viscera (organs). Visceral structures are highly sensitive to distension (stretch), ischemia and inflammation, but relatively insensitive to other stimuli that normally evoke pain such as cutting or burning. Reported causative or associated events include sprains, bone fractures, burns, bumps, bruises, inflammation (from an infection or arthritic disorder), obstructions, and myofascial pain.
Neuropathic pain is a complex, chronic pain state that usually is accompanied by tissue injury. With neuropathic pain, the nerve fibers themselves may be damaged, dysfunctional, or injured. These damaged nerve fibers send incorrect signals to other pain centers. This is often associated with lesions or disease affecting the somatosensory nervous system either in the periphery or centrally. Reported causative factors for neuropathic pain include painful polyneuropathy, postherpetic neuralgia, trigeminal neuralgia, and post-stroke pain. Neuropathic pain is also understood to arise from cancer, a neurological disorder, spine or peripheral nerve surgery, a brain tumor, traumatic brain injury (TBI), spinal cord trauma, a chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, a neuralgia, lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, ALS, Parkinson's disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, a bony fracture, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II (CRPS III), radiculopathy, Guillain-barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, vulvodynia or vidian neuralgia.

[makemydaze]

Thanks Greenspam3 for the patent update re: AV1066.

https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=BC408884301C92C138395C4C99A39D55.wapp1nC?docId=US243292967&tab=PCTDESCRIPTION&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&recNum=1&maxRec=38

Here's part of the verbiage from the patent claims(from the link above):

"Without being bound by any particular theory, AV-1066 has a positive effect on the hypersensitivity likely due to the nerve constriction. At any moment, treated animals with AV-1066, whatever the dose, came back to values observed to the intact hind paw (max effect+59%)."

and from the poster presentation for 1066:

• AV1066 produced a dose-dependent reversal of the hypersensitivity that develops in animal models of both neuropathic and visceral pain.

• The reversal of the hypersensitivity with AV1066 appeared to be complete as drug treated levels and vehicle-treated / sham levels were indistinguishable. • AV1066 had no significant effect on the rate of intestinal transit, a surrogate marker for constipation, at doses in which it relieved visceral pain, and demonstrated only a limited effect in the Irwin Grid, a behavioral battery commonly used in estimating general safety and toleration.

In the CCI model of neuropathic pain, AV1066 did not impact nociception in the contralateral healthy paw in contrast to morphine, which has an analgesic effect in both paws. This suggests that AV1066 acts in a state-selective manner and only impacts nociception during periods of pathophysiological stress.

http://www.anavex.com/wp-content/uploads/AV-1066-poster-November-2016.pdf

The bolded part(which I highlighted) has me wondering if there is any oral heavy duty pain reliever that only affects the part of the body that is experiencing pain? I'm of the opinion that most available heavy duty oral pain medications have a whole body effect but I'm no authority.

And it looks like 1066 may have anti-tumor as well:

"ANAVEX 1066, a mixed Sigma-1/Sigma-2 receptor ligand, has previously demonstrated antitumor activity as well as analgesic effects in an animal model of chemotherapy-induced polyneuropathy."

https://www.globenewswire.com/news-release/2016/11/14/889538/0/en/Anavex-Life-Sciences-Novel-Sigma-1-Sigma-2-Ligand-Shows-Encouraging-Results-as-an-Analgesic-in-Animal-Models-of-Neuropathic-and-Visceral-Pain.html

The potential of this sigma receptor platform is off the charts. IMO